Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Retained Earnings (2016 - 2026)

Pharma-Bio Serv's Retained Earnings history spans 16 years, with the latest figure at $280358.0 for Q1 2026.

  • For Q1 2026, Retained Earnings rose 14.96% year-over-year to $280358.0; the TTM value through Jan 2026 reached $280358.0, up 14.96%, while the annual FY2025 figure was $10.5 million, 3914.63% up from the prior year.
  • Retained Earnings reached $280358.0 in Q1 2026 per PBSV's latest filing, down from $10.5 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $16.3 million in Q1 2022 to a low of $67823.0 in Q2 2022.
  • Average Retained Earnings over 5 years is $5.0 million, with a median of $280358.0 recorded in 2026.
  • Peak YoY movement for Retained Earnings: plummeted 99.67% in 2022, then surged 21094.48% in 2023.
  • A 5-year view of Retained Earnings shows it stood at $238152.0 in 2022, then dropped by 11.71% to $210266.0 in 2023, then rose by 24.78% to $262380.0 in 2024, then skyrocketed by 3914.63% to $10.5 million in 2025, then plummeted by 97.34% to $280358.0 in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Retained Earnings are $280358.0 (Q1 2026), $10.5 million (Q4 2025), and $285577.0 (Q3 2025).